Department of Anaesthesiology and Intensive Care, Hannover Medical School, Carl-Neuberg-Str. 1, D-30625 Hannover, Germany.
Br J Anaesth. 2010 May;104(5):555-62. doi: 10.1093/bja/aeq058. Epub 2010 Mar 26.
Normalization of plasma fibrinogen levels may be associated with satisfactory haemostasis and reduced bleeding. The aim of this retrospective study was to assess fibrinogen recovery parameters after administration of fibrinogen concentrate (Haemocomplettan P) to patients with diffuse bleeding in cardiovascular surgery. Data on transfusion and patient outcomes were also collected.
Patient characteristic and clinical data were obtained from patient records.
of the thromboelastometry (FIBTEM)and of the standard coagulation tests, including plasma fibrinogen level, measured before surgery, before and after haemostatic therapy, and on the following day, were retrieved from laboratory records. Results Thirty-nine patients receiving fibrinogen concentrate for diffuse bleeding requiring haemostatic therapy after cardiopulmonary bypass were identified. The mean fibrinogen concentrate dose administered was 6.5 g. The mean fibrinogen level increased from 1.9 to 3.6 g litre(-1) (mean increment of 0.28 g litre(-1) per gram of concentrate administered); maximum clot firmness increased from 10 to 21 mm. The mean fibrinogen increase was 2.29 (sd 0.7) mg dl(-1) per mg kg(-1) bodyweight of concentrate administered. Thirty-five patients received no transfusion of fresh-frozen plasma (FFP) or platelet concentrate after receiving fibrinogen concentrate; the remaining four patients received platelet concentrate intraoperatively. Eleven patients received platelets, FFP, or both during the first postoperative day. No venous thromboses, arterial ischaemic events, or deaths were registered during hospitalization.
In this retrospective study, fibrinogen concentrate was effective in increasing plasma fibrinogen level, and contributed to the correction of bleeding after cardiovascular surgery.
血浆纤维蛋白原水平的正常化可能与满意的止血和减少出血有关。本回顾性研究的目的是评估在心血管手术弥漫性出血患者中给予纤维蛋白原浓缩物(Haemocomplettan P)后纤维蛋白原恢复参数。还收集了输血和患者结局的数据。
从患者记录中获取患者特征和临床数据。
从实验室记录中检索了血栓弹性描记术(FIBTEM)和标准凝血试验的结果,包括手术前、止血治疗前后以及次日的血浆纤维蛋白原水平。结果:确定了 39 例因体外循环后弥漫性出血需要止血治疗而接受纤维蛋白原浓缩物的患者。给予的纤维蛋白原浓缩物平均剂量为 6.5 g。纤维蛋白原水平从 1.9 增加到 3.6 g/L(每给予 1 g 浓缩物平均增加 0.28 g/L);最大凝块硬度从 10 增加到 21 mm。给予的纤维蛋白原平均增加量为 2.29(sd 0.7)mg/dl 每 mg/kg 给予的浓缩物体重。35 例患者在接受纤维蛋白原浓缩物后未输注新鲜冷冻血浆(FFP)或血小板浓缩物;其余 4 例患者在术中接受了血小板浓缩物。11 例患者在术后第 1 天接受了血小板、FFP 或两者。住院期间未发生静脉血栓形成、动脉缺血性事件或死亡。
在这项回顾性研究中,纤维蛋白原浓缩物有效地增加了血浆纤维蛋白原水平,并有助于纠正心血管手术后的出血。